Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 10/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.66 |
| ▸ | GRIA4 | P48058 | 11/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101398 | 1.00 | GRIA2 (0.66) | GRIA2KCNH2GRIA4 | |
| SCHEMBL4101394 | 1.00 | GRIA2 (0.66) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2189590 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2189825 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2188773 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2188780 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2188771 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2191014 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2191013 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 | |
| SCHEMBL2189760 | 0.88 | GRIA4 (0.68) | GRIA2KCNH2GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GRIN2C, GRIN1, OXER1 | GRIA2 27/4885KCNH2 1331/4885GRIA4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.